Healthcare Industry News: Elixir Pharmaceuticals
News Release - September 17, 2013
InVivo Therapeutics Appoints Gregory D. Perry as Interim CFOCAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--InVivo Therapeutics Holdings Corp. (NVIV), a drug delivery company with a focus on groundbreaking technologies for the treatment of spinal cord injuries (SCI) and neurotrauma conditions, today announced that Gregory D. Perry has been appointed as interim CFO, commencing September 23, 2013.
Mr. Perry was most recently the Executive Vice President and CFO of Immunogen, Inc. Prior to joining Immunogen, Mr. Perry served as CFO of Elixir Pharmaceuticals, Inc. from 2007 to 2009. Prior to Elixir, he was CFO of Domantis Ltd., which was acquired by GlaxoSmithKline in 2006. Previously, Mr. Perry was Senior Vice President and CFO of Transkaryotic Therapies, Inc. until its acquisition by Shire plc in 2005. Mr. Perry is currently a member of the Board of Directors of Advanced Cell Technology, Inc.
"We are excited to bring on board a CFO with the integrity, talent and experience of Greg Perry,” said Mike Astrue, the interim CEO of InVivo. "His breadth of experience can add value to InVivo in a variety of ways."
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments for serious diseases and conditions, including improving function in individuals paralyzed as a result of traumatic spinal cord injury. The Company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the Company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit, www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Institutional Review Board process, the Company’s ability to obtain FDA approval to commercialize its products, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and other risks associated with the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies identified and described in more detail in our filings with the SEC, including our Form 10-K and 10-Q’s and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.
Source: InVivo Therapeutics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.